Most recently, CRISPR-Cas9 gene therapy was used to “un-silence” the dormant paternally inherited UBE3A allele during the prenatal and early postnatal period, rescuing the expected anatomical and behavioral phenotypes associated with Angelman syndrome [89]. This evidence concerns the gene UBE3A and Angelman syndrome.